STAT3 and neoplasm: Specifically, ASGR1 interacts with Nemo-like kinase (NLK) to inhibit glycoprotein 130/janus kinase 1 (GP130/JAK1)-mediated STAT3 phosphorylation, thereby blocking the activation of STAT3-related pro-tumor signaling pathways (92).